CJC-1295 (without DAC) 10mg + Ipamorelin 10mg

CJC-1295 without DAC and Ipamorelin are combined here as a dual-pathway research blend. The CJC component is a short-acting GHRH analogue, while Ipamorelin targets the ghrelin receptor GHS-R1a. The pairing is studied for coordinated pituitary GH signalling and receptor-pathway interactions.Research-use reference: No dosing or human-use recommendation is implied. Verify the exact composition and legal status of your batch before publication.